{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:58:10Z","timestamp":1781089090270,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00277-020-04384-w","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T20:02:50Z","timestamp":1609704170000},"page":"437-443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS\/SMM to newly diagnosed and relapsed multiple myeloma"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-180X","authenticated-orcid":false,"given":"Stefania","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"De Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Caltagirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Troia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Oddolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Gilestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Saraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Margiotta Casaluci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Genuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Omed\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"4384_CR1","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JMC, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997. https:\/\/doi.org\/10.1038\/ncomms3997","journal-title":"Nat Commun"},{"key":"4384_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.CCR.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Getz G, Golub TR, Anderson KC, Richardson P, Krishnan A, Lonial S, Kaufman J, Siegel DS, Vesole DH, Roy V, Rivera CE, Rajkumar SV, Kumar S, Fonseca R, Ahmann GJ, Bergsagel PL, Stewart AK, Hofmeister CC, Efebera YA, Jagannath S, Chari A, Trudel S, Reece D, Wolf J, Martin T, Zimmerman T, Rosenbaum C, Jakubowiak AJ, Lebovic D, Vij R, Stockerl-Goldstein K (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25:91\u2013101. https:\/\/doi.org\/10.1016\/J.CCR.2013.12.015","journal-title":"Cancer Cell"},{"key":"4384_CR3","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ (2015) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33:3911\u20133920. https:\/\/doi.org\/10.1200\/JCO.2014.59.1503","journal-title":"J Clin Oncol"},{"key":"4384_CR4","doi-asserted-by":"publisher","unstructured":"Fonseca R (2003) Many and multiple myeloma(s). Leukemia 17:1943\u20131944.\u00a0https:\/\/doi.org\/10.1038\/sj.leu.2403090","DOI":"10.1038\/sj.leu.2403090"},{"key":"4384_CR5","doi-asserted-by":"publisher","unstructured":"Fonseca R, Barlogie B, Bataille R et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546\u20131558.\u00a0https:\/\/doi.org\/10.1158\/0008-5472.can-03-2876","DOI":"10.1158\/0008-5472.can-03-2876"},{"key":"4384_CR6","doi-asserted-by":"publisher","unstructured":"Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335\u2013348.\u00a0https:\/\/doi.org\/10.1038\/nrc3257","DOI":"10.1038\/nrc3257"},{"key":"4384_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell PC (1976) The clonal evolution of tumor cell populations. Science (80- ) 194:23\u201328. https:\/\/doi.org\/10.1126\/science.959840","journal-title":"Science (80- )"},{"key":"4384_CR8","doi-asserted-by":"publisher","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501:338\u2013345.\u00a0https:\/\/doi.org\/10.1038\/nature12625","DOI":"10.1038\/nature12625"},{"key":"4384_CR9","doi-asserted-by":"publisher","unstructured":"Corre J, Munshi N, Avet-Loiseau H (2015) Genetics of multiple myeloma: another heterogeneity level? Blood 125:1870\u20131876.\u00a0https:\/\/doi.org\/10.1182\/blood-2014-10-567370","DOI":"10.1182\/blood-2014-10-567370"},{"key":"4384_CR10","doi-asserted-by":"publisher","unstructured":"Robiou Du Pont S, Cleynen A, Fontan C et al (2017) Genomics of multiple myeloma. J Clin Oncol 35:963\u2013967.\u00a0https:\/\/doi.org\/10.1200\/jco.2016.70.6705","DOI":"10.1200\/jco.2016.70.6705"},{"key":"4384_CR11","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H, International Myeloma Working Group (2009) International myeloma working group molecular classification of multiple myeloma: spotlight review. Leukemia 23:2210\u20132221. https:\/\/doi.org\/10.1038\/leu.2009.174","journal-title":"Leukemia"},{"key":"4384_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic (2013) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 88:360\u2013376. https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.019","journal-title":"Mayo Clin Proc"},{"key":"4384_CR13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","volume":"30","author":"H Avet-Loiseau","year":"2012","unstructured":"Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P (2012) Long-term analysis of the ifm 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 30:1949\u20131952. https:\/\/doi.org\/10.1200\/JCO.2011.36.5726","journal-title":"J Clin Oncol"},{"key":"4384_CR14","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1182\/blood.V90.9.3682","volume":"90","author":"M Zandecki","year":"1997","unstructured":"Zandecki M, La\u00ef JL, Genevi\u00e8ve F et al (1997) Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood 90:3682\u20133690","journal-title":"Blood"},{"key":"4384_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","volume":"17","author":"L L\u00f3pez-Corral","year":"2011","unstructured":"L\u00f3pez-Corral L, Guti\u00e9rrez NC, Vidriales MB et al (2011) The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 17:1692\u20131700. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1066","journal-title":"Clin Cancer Res"},{"key":"4384_CR16","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1182\/blood.V86.10.3915.bloodjournal86103915","volume":"86","author":"J Drach","year":"1995","unstructured":"Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, J\u00e4ger U, Fiegl M, Geissler K, Ludwig H, Huber H (1995) Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86:3915\u20133921","journal-title":"Blood"},{"key":"4384_CR17","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/leu.2014.59","volume":"28","author":"S Zhao","year":"2014","unstructured":"Zhao S, Choi M, Heuck C, Mane S, Barlogie B, Lifton RP, Dhodapkar MV (2014) Serial exome analysis of disease progression in premalignant gammopathies. Leukemia 28:1548\u20131552. https:\/\/doi.org\/10.1038\/leu.2014.59","journal-title":"Leukemia"},{"key":"4384_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Guti\u00e9rrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ (2014) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28:384\u2013390. https:\/\/doi.org\/10.1038\/leu.2013.199","journal-title":"Leukemia"},{"key":"4384_CR19","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","volume":"102","author":"A Mikulasova","year":"2017","unstructured":"Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617\u20131625. https:\/\/doi.org\/10.3324\/haematol.2017.163766","journal-title":"Haematologica"},{"key":"4384_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, Hewett DR, Zannettino ACW (2019) Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability. Leukemia 33:457\u2013468. https:\/\/doi.org\/10.1038\/s41375-018-0206-x","journal-title":"Leukemia"},{"key":"4384_CR21","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, Martincorena I, Dawson KJ, Samur MK, Zamora J, Tarpey P, Davies H, Fulciniti M, Shammas MA, Tai YT, Magrangeas F, Moreau P, Corradini P, Anderson K, Alexandrov L, Wedge DC, Avet-Loiseau H, Campbell P, Munshi N (2018) Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9:3363. https:\/\/doi.org\/10.1038\/s41467-018-05058-y","journal-title":"Nat Commun"},{"key":"4384_CR22","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, Snir N, Magen H, Koren-Michowitz M, Herzog-Tzarfati K, Keren-Shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-Urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-Miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I (2018) Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med 24:1867\u20131876. https:\/\/doi.org\/10.1038\/s41591-018-0269-2","journal-title":"Nat Med"},{"key":"4384_CR23","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","volume":"1","author":"S Mailankody","year":"2017","unstructured":"Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O (2017) Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv 1:1911\u20131918. https:\/\/doi.org\/10.1182\/bloodadvances.2017005934","journal-title":"Blood Adv"},{"key":"4384_CR24","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.3324\/haematol.2017.184358","volume":"103","author":"B Gerber","year":"2018","unstructured":"Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A (2018) Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica 103:e245\u2013e248. https:\/\/doi.org\/10.3324\/haematol.2017.184358","journal-title":"Haematologica"},{"key":"4384_CR25","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","volume":"32","author":"J Corre","year":"2018","unstructured":"Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M, Munshi N, Avet-Loiseau H (2018) Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia 32:2636\u20132647. https:\/\/doi.org\/10.1038\/s41375-018-0153-6","journal-title":"Leukemia"},{"key":"4384_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Zhan F, Sawyer J et al (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296\u2013303. https:\/\/doi.org\/10.1182\/blood-2005-01-0034","journal-title":"Blood"},{"key":"4384_CR27","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1158\/1078-0432.CCR-12-3866","volume":"19","author":"B H\u00e9braud","year":"2013","unstructured":"H\u00e9braud B, Caillot D, Corre J et al (2013) The translocation t(4;14) can be present only in minor subclones in multiple myeloma. Clin Cancer Res 19:4634\u20134637. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3866","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04384-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-04384-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04384-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T05:07:12Z","timestamp":1611119232000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-04384-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["4384"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04384-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SO has received honoraria from Amgen, Celgene, and Janssen and has served on the advisory boards for Adaptive Biotechnologies, Janssen, Amgen, and Takeda. MD has received honoraria for lectures from Sanofi and GSK and has served on the advisory boards for GSK. RM has received honoraria from Sanofi, Celgene, Takeda, and Janssen; has served on the advisory boards for Sanofi, Takeda, and Janssen; and has received consultancy fees from Janssen. SB has received honoraria from Celgene, Amgen, Janssen, and Bristol-Myers Squibb; has served on the advisory boards for Celgene, Amgen, Janssen, and Karyopharm; and has received consultancy fees from Janssen and Takeda. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GSK; and has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. PO has served on the advisory boards for Janssen. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Patients gave written informed consent before bone marrow aspiration and before starting therapy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}